Depressed Patients’ Perspectives of 2 Measures of Outcome: The Quick Inventory of Depressive Symptomatology (QIDS) and the Remission from Depression Questionnaire (RDQ)
Restricted accessResearch articleFirst published online August, 2011
Depressed Patients’ Perspectives of 2 Measures of Outcome: The Quick Inventory of Depressive Symptomatology (QIDS) and the Remission from Depression Questionnaire (RDQ)
Current operational definitions of remission, at their root, are exclusively symptom-based and therefore limited in scope. In this report from the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project we examined patient acceptability of a new measure, the Remission from Depression Questionnaire (RDQ), a scale designed to capture a broader array of domains patients consider relevant to the construct of remission. Patient acceptance of the RDQ was compared with that of the Quick Inventory of Depressive Symptomatology (QIDS), the instrument used to measure outcome in the Sequenced Treatment Alternatives to Relieve Depression study.
Methods
One hundred and two depressed outpatients in ongoing treatment completed the RDQ, QIDS, and a 9-item measure of patient preference.
Results
Patients indicated the RDQ was a better indicator of their overall state and treatment goals. Patients judged the RDQ to be a more accurate and preferred measure to determine treatment outcome, and a more accurate indicator of remission.
Conclusions
Patients considered the multifactorial RDQ a more accurate indicator of their treatment goals than a purely symptom measure such as the QIDS.
St. LouisEK.MinimizingAEDadverse effects: Improving quality of life in the interictal state in epilepsy care. Curr Neuropharmacol. 2009;7:106–114.
2.
ColognoD, TorelliP, ManzoniGC.Possible predictive factors in the prognosis of migraine with aura. Cephalalgia. 1999;19:824–830.
3.
WhitworthJA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983–1992.
4.
Keller PastMB., present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289:3152–3160.
5.
RushAJ, KraemerHC, SackeimHA, . Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31:1841–1853.
6.
CuffelB, AzocarF, TomlinM, . Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J Clin Psychiatry. 2003;64:397–402.
7.
SheltonRC, TomarkenAJ.Can recovery from depression be achieved? Psychiatr Serv. 2001;52:1469–1478.
8.
Practice guideline for the treatment of patients with major depressive disorder (revision).Washington, DC:American Psychiatric Association; 2000.
9.
AndersonIM, NuttDJ, DeakinJF.qEvidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2000;14:3–20.
10.
StahlS.Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy. J Clin Psychiatry. 1999;60:213–214.
11.
ThaseME.Defining remission in patients treated with antidepressants. J Clin Psychiatry. 1999;60:(suppl 22)3–6,35-36.
12.
FaravelliC, AmbonettiA, PallantiS, . Depressive relapses and incomplete recovery from index episode. Am J Psychiatry. 1986;143:888–891.
13.
PaykelES, RamanaR, CooperZ, . Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171–1180.
14.
SimonsAD, MurphyGE, LevineJL.Relapse after treatment with cognitive therapy and/or pharmacotherapy: results after one year. Arch Gen Psychiatry. 1986;43:43–48.
15.
EversonSA, RobertRE, GoldbergDE, . Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med. 1998;158:1133–1138.
16.
JuddLL, AkiskalHS, PaulusMP.The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord. 1997;45:5–18.
17.
MurphyJ, MonsonR, OlivierD, . Affective disorders and mortality. A general population study. Arch Gen Psychiatry. 1987;44:473–480.
18.
VaccarinoV, KaslSV, AbramsonJ, . Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol. 2001;38:199–205.
19.
MillerIW, KeitnerGI, SchatzbergAF, . The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59:608–619.
20.
WellsKB, StewartA, HayesRD, . The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914–919.
21.
ZimmermanM, McGlincheyJB, PosternakMA, . How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry. 2006;163:148–150.
22.
RushAJ, TrivediMH, IbrahimHM, . The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–583.
23.
TrivediMH, RushAJ, WisniewskiSR, , and the STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
24.
ZimmermanM, McGlincheyJB, PosternakMA, . Remission in depressed patients: more than just symptom resolution. J Psychiatr Res. 2008;42:797–801.
25.
GilbodyS, HouseA, SheldonT.Psychiatrists in the UK do not use outcomes measures. National survey. Br J Psychiatry. 2002;180:101–103.
26.
ZimmermanM, McGlincheyJB.Why don't psychiatrists use scales to measure outcome when treating depressed patients?J Clin Psychiatry. 2008; 69:1916–1919.
27.
ZimmermanM, McGlincheyJB, ChelminskiI.An inadequate community standard of care: lack of measurement of outcome when treating depression in clinical practice. Prim psychiatry. 2008;15:67–75.
28.
TrivediMH, RushAJ, GaynesBN, . Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology. 2007;32:2479–2489.
